Head to Head Review: Kymera Therapeutics (NASDAQ:KYMR) and Genus (OTCMKTS:GENSF)

Kymera Therapeutics (NASDAQ:KYMR) and Genus (OTCMKTS:GENSF) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Analyst Ratings

This is a summary of current ratings for Kymera Therapeutics and Genus, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	0	6	6	0	2.50
Genus	0	0	0	0	N/A

Kymera Therapeutics currently has a consensus price target of $41.10, suggesting a potential upside of 15.13%. Given Kymera Therapeutics’ higher possible upside, equities research analysts plainly believe Kymera Therapeutics is more favorable than Genus.

Insider & Institutional Ownership

29.7% of Genus shares are owned by institutional investors. 15.8% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Kymera Therapeutics and Genus’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$78.59 million	27.87	-$146.96 million	($2.51)	-14.22
Genus	N/A	N/A	N/A	$0.48	48.32

Genus has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kymera Therapeutics and Genus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-194.67%	-31.92%	-23.98%
Genus	N/A	N/A	N/A

Summary

Genus beats Kymera Therapeutics on 6 of the 10 factors compared between the two stocks.

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

About Genus

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers technical services to farmers. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.